ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
6.04
-0.27 (-4.28%)
Oct 6, 2026, 4:00 PM EDT - Market closed
ENDRA Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.74 | 0.76 | 3.23 | 2.83 | 4.89 | 9.46 |
Cash & Short-Term Investments | 1.74 | 0.76 | 3.23 | 2.83 | 4.89 | 9.46 |
Cash Growth | -3.79% | -76.39% | 13.96% | -42.04% | -48.33% | 30.91% |
Inventory | - | - | - | - | - | 1.28 |
Prepaid Expenses | 0.05 | 0.21 | 0.2 | 0.2 | 0.49 | 1.35 |
Total Current Assets | 5.59 | 0.97 | 3.43 | 3.03 | 5.38 | 12.09 |
Property, Plant & Equipment | 0.44 | 0.5 | 0.65 | 0.47 | 0.74 | 0.77 |
Other Long-Term Assets | 1.91 | 2.38 | 0.37 | 3.26 | 3.15 | 0.01 |
Total Assets | 7.94 | 3.85 | 4.45 | 6.75 | 9.27 | 12.87 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.46 | 0.38 | 0.27 | 0.36 | 0.61 | 0.79 |
Accrued Expenses | 0.18 | 0.24 | 0.24 | 0.19 | 0.75 | 0.5 |
Short-Term Debt | - | - | - | 0.15 | 0.16 | 0.12 |
Current Portion of Long-Term Debt | - | - | - | 0.03 | 0.03 | - |
Current Portion of Leases | 0.14 | 0.13 | 0.1 | 0.17 | 0.15 | 0.13 |
Total Current Liabilities | 0.79 | 0.75 | 0.61 | 0.9 | 1.7 | 1.54 |
Long-Term Debt | - | - | - | - | - | 0.03 |
Long-Term Leases | 0.29 | 0.36 | 0.49 | 0.19 | 0.37 | 0.52 |
Other Long-Term Liabilities | 0.56 | 0.48 | 0.8 | - | - | - |
Total Liabilities | 1.63 | 1.59 | 1.89 | 1.1 | 2.07 | 2.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 118 | 112.73 | 106 | 97.58 | 89.07 | 79.46 |
Retained Earnings | -111.62 | -110.47 | -103.44 | -91.93 | -81.87 | -68.69 |
Comprehensive Income & Other | -0.07 | - | - | 0.01 | 0.01 | 0.01 |
Total Common Equity | 6.31 | 2.26 | 2.56 | 5.66 | 7.2 | 10.78 |
Shareholders' Equity | 6.31 | 2.26 | 2.56 | 5.66 | 7.2 | 10.78 |
Total Liabilities & Equity | 7.94 | 3.85 | 4.45 | 6.75 | 9.27 | 12.87 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.43 | 0.49 | 0.58 | 0.54 | 0.71 | 0.8 |
Net Cash (Debt) | 1.31 | 0.27 | 2.65 | 2.29 | 4.18 | 8.67 |
Net Cash Growth | 4.76% | -89.79% | 15.47% | -45.25% | -51.72% | 34.18% |
Net Cash Per Share | 1.19 | 0.34 | 13.09 | - | - | - |
Filing Date Shares Outstanding | 1.5 | 1.24 | 0.56 | - | - | - |
Total Common Shares Outstanding | 1.5 | 1.18 | 0.54 | - | - | - |
Working Capital | 4.8 | 0.22 | 2.83 | 2.13 | 3.68 | 10.55 |
Book Value Per Share | 4.21 | 1.92 | 4.77 | - | - | - |
Tangible Book Value | 6.31 | 2.26 | 2.56 | 5.66 | 7.2 | 10.78 |
Tangible Book Value Per Share | 4.21 | 1.92 | 4.77 | - | - | - |